To verify whether altered glial glutamate uptake contributes to the reduced efficacy of glutamatergic transmission reported in the prefrontal cortex of schizophrenics, we studied the expression of GLT-1, the transporter responsible for most glutamate transport, in autoptic samples of prefrontal cortex using real time quantitative RT-PCR, immunocytochemistry, and functional assays. GLT-1 mRNA levels in medication-free patients were 2.5-fold higher than in controls, whereas they were normal or reduced in patients treated with antipsychotics. We also observed a 4-fold increase in L-[ 3 H]-Glu uptake in Xenopus oocytes injected with mRNA from the prefrontal cortex of a medication-free schizophrenic and a 2-fold increase in GLT-1 protein in the same cortical area of another medication-free patient. Results suggest that GLT-1 mRNA, protein and function are increased in prefrontal cortex of schizophrenics. Following the demonstration that the psychotomimetic drug phencyclidine blocks NMDA subtypes of glutamate (Glu) receptors, several studies have provided evidence that in schizophrenics an altered function of NMDA receptors may reduce glutamatergic transmission in cortical circuits pivoting in the prefrontal cortex (Tsai and Coyle, 2002) .
Following the demonstration that the psychotomimetic drug phencyclidine blocks NMDA subtypes of glutamate (Glu) receptors, several studies have provided evidence that in schizophrenics an altered function of NMDA receptors may reduce glutamatergic transmission in cortical circuits pivoting in the prefrontal cortex (Tsai and Coyle, 2002) .
Reduced neocortical glutamatergic signaling can also result from other mechanisms. Glu transporters are important regulators of excitatory transmission and are essential for maintaining physiological Glu levels (Conti and Weinberg, 1999; Danbolt, 2001) ; increased Glu uptake may thus reduce the efficacy of glutamatergic transmission. The possibility that increased Glu uptake plays a role in the pathophysiology of schizophrenia is suggested by the demonstration that in rat frontal cortex the antipsychotic clozapine reduces the expression and function of GLT-1-the plasma membrane transporter responsible for most Glu transport (Rothstein et al., 1996; Tanaka et al:, 1997 )-in a strong and selective manner, thereby raising extracellular Glu levels (Melone et al., 2001 (Melone et al., , 2003 .
We studied 25 samples from the prefrontal cortex (PFC) of 11 schizophrenics and 14 subjects without neurological or psychiatric diseases (hereinafter referred to as controls); 3 of the 11 schizophrenics had not received antipsychotic drugs for an amount of time sufficient to rule out their influence (Baldessarini and Tarazi, 2001 ), allowing to test more directly the hypothesis that GLT-1 overexpression contributes to reducing glutamatergic transmission in schizophrenics. and cDNA was synthesized with a reverse transcription kit (Applied Biosystems, Madrid, Spain) using random hexamers. Real-time quantitative RT-PCR (rtqRT-PCR) was carried out in an ABI PRISM 7000 Sequence Detection System instrument (Applied Biosystems) with primers designed by PrimerExpress software (Applied Biosystems) to specifically hybridize GLT-1 transcripts. Cyclophilin A, GAPDH, and ␤ 2 -microglobulin housekeeping genes were used as endogenous references to normalize the variability in the initial quantities of total RNA and allow accurate comparison of gene expression levels between samples.
Tissue blocks (0.5 cm thick) from areas 9/46 (Rajkowska and Goldman-Rakic, 1995) of 4 controls [nos. 4586, 4981, 4605, and 4735] and one medication-free patient (no. 3259) were postfixed in 4% PFA, exposed to microwave pre-treatment (Evers and Uylings, 1994) , and cut into 30-m-thick sections. For immunoperoxidase, sections were processed (in parallel to minimize possible procedural variations) as described previously using antibodies directed against GLT-1 (Rothstein et al., 1994) (0.008 g/ml) or against GFAP (1:800; Sigma, GA5, G-3893). For quantitative analysis, 6 strips (56 -93 serial images from the pia to the white matter/case) from 2 sections of each control and of one medication-free patient were reconstructed; all images were from sections processed in parallel. Density values were obtained with the Zeiss KS400 image analysis software (v. 2.0); mean density was calculated for each case. For immunofluorescence, sections were processed using GLT-1 (1:800; Chemicon, AB1783) and GPAP (1:800; Sigma, GA5, G-3893) antibodies; FITC-(Vector, FI7000) and TRITC-(Molecular Probes, T2762/6691-1)-conjugated secondary antibodies (1:100) were used to detect GLT-1 and GPAP. Sections were examined using a Bio-Rad confocal microscope as described (Minelli et al., 2001 ). For Western blotting, frozen samples were processed as described (Melone et al., 2001 ). Labeled band visualization and analysis were performed using the Chemidoc and Quantity One software (Bio-Rad version 4.1.1).
mRNA from PFC of 3 controls (nos. 4735, 4265, and 4605) and one medication-free schizophrenic (no. 3564) was purified by oligo (dT)-cellulose chromatography. Xenopus oocyte harvesting, injection, and collagenase treatment were as described (Matute and Miledi, 1993) . All oocytes were injected with the same amount of mRNA (50 ng). Sodium-dependent, dihydrokainate (DHK)-sensitive, L-[ 3 H]-Glu (1 M; 46 Ci/mmol; Amersham) uptake was measured by incubating injected oocytes in frog's Ringer for 30 min at room temperature as described (Melone et al., 2001) . Glu transport was measured 4 days after injection and calculated by subtracting the total amount of radioactivity from that observed in non-injected oocytes. DMSO did not affect the levels of radioactivity measured in uptake experiments.
GLT-1 gene expression studies in the PFC of schizophrenics and controls by rtqRT-PCR showed that GLT-1 mRNA was increased 2.38 Ϯ 0.4-fold (P Ͻ 0.05) in medication-free patients (n ϭ 2), slightly increased (1.33 Ϯ 0.25-fold) in 3 patients treated with atypical antipsychotics (clozapine, olanzapine, and risperidone) and reduced (0.34 Ϯ 0.09-fold; P Ͻ 0.001) in the 5 patients treated with typical antipsychotics (haloperidol [n ϭ 3], perphenazine [n ϭ 1], and thioridazine [n ϭ 1]) (Fig. 1) .
We then studied GLT-1 protein expression by immunocytochemistry in a specimen from a medication-free patient and in controls. In the latter, GLT-1 immunoreactivity (ir) was as described previously (Milton et Fig. 1 . Expression of GLT-1 mRNA in PFC of schizophrenics. GLT-1 mRNA levels are increased in medication-free patients, and reduced or unchanged after treatment with typical or atypical antipsychotics respectively. Values were internally normalized using three housekeeping genes and then compared with those obtained in ageand gender-matched controls. Values are means Ϯ SEM (n ϭ 2-5), *P Ͻ 0.05, ***P Ͻ 0.001.
al., 1997; Tessler et al., 1999) (Fig. 2A,C) ; adjacent sections stained for Nissl and GFAF were normal . In the medication-free schizophrenic, the extent and the intensity of GLT-1 ir were both robustly increased (Fig. 2B,D) . To rule out the possibility that increased GLT-1 expression was deter- Fig. 2 . Increased levels of GLT-1 in PFC of a schizophrenic patient. GLT-1 in areas 9 -46 of a control (A,C) and a medication-free schizophrenic (B,D). E: Immunoblots of GLT-1 from homogenates of areas 9/46 of a control and a medication-free schizophrenic reveal a single band. F,G: GLT-1 (green)-GFAP (red) colocalization studies show that in both controls (F) and the medication-free schizophrenic (G) GLT-1 is localized to astrocytes. H,I: Densitometric analysis of GLT-1 ir shows that it increased in the schizophrenic compared with four different controls (H) but without a laminar preference (I). Values are means Ϯ SEM; significance analyzed with a two-tailed unpaired ttest; P Ͻ 0.01. SEM in I refer to the value obtained in the four controls; Roman numerals indicate cortical layers. Scale bars ϭ 500 m for A and B; 50 m for C and D; 25 m for G and F.
mined by cross-reaction with novel proteins, blocks of areas 9/46 from a control and the medication-free patient were used for Western studies; the GLT-1 antibody revealed a single band of ϳ70 kDa (Fig. 2E) , consistent with the known molecular weight of GLT-1. To rule out the possibility that increased GLT-1 ir was related to a switch in its cellular expression, we performed GLT-1/GFAP double-labeling studies in sections from the same two specimens; these studies showed that, as in controls, GLT-1 colocalized with GFAP (Fig. 2F,G) and was never expressed in neurons. We then performed densitometric analysis of GLT-1 ir to quantitate the increase and to ascertain whether the increase was layer-specific; the results showed that GLT-1 increased by 83.79% in the medication-free schizophrenic compared with controls (Fig. 2H) , and that it did not display any significant laminar preference (Fig. 2I) .
Finally, we measured L-3 [H]-Glu uptake in Xenopus laevis oocytes injected with mRNA extracted from the PFC of a medication-free patient and of controls and found that Na ϩ -dependent, DHK-sensitive Glu transport was consistently almost 4-fold greater than in oocytes injected with mRNAs from controls (increase range 3.3-3.8-fold, average 3.6; Fig. 3) .
A reduction in Glu-mediated synaptic transmission in the prefrontal cortex may contribute to generating at least some of the symptoms observed in schizophrenics (Tsai and Coyle, 2002) . Our previous studies of the effects of clozapine on the expression and function of Glu transporters in rat frontal cortex (Melone et al., 2001 (Melone et al., , 2003 have suggested that, as in the thalamus (Smith et al., 2001 ), GLT-1 may be overexpressed in the cerebral cortex of schizophrenics. RtqRT-PCR, immunocytochemical, and functional studies reported here, particularly those from the rare specimens of the three medication-free schizophrenic patients showing abnormally high GLT-1 expression in the PFC, indicate that the hypothesis that GLT-1 is overexpressed in schizophrenics is tenable and merits large-scale studies. In the present and in previous studies (Minelli et al., 2001; Melone et al., 2001) , we observed GLT-1 ir exclusively in astrocytic processes, in line with the results of most reports (Danbolt, 2001) . Recently, Chen et al. (2004) , using the same antibody used here, reported that in the hippocampus of animals perfused without glutaraldehyde only 65-70% of immunoreactivity was astrocytic, the remaining being neuronal. Even though these findings await confirmation in neocortical areas of humans, they raise the possibility that the changes reported here may not depend on altered astrocytic GLT-1 expression alone. Finally, the observation that in patients treated with antipsychotics the levels of GLT-1 mRNA are normal or reduced indicates that these drugs are negative regulators of GLT-1 expression and that they affect differentially its expression, as suggested by previous studies in rats (Schneider et al., 1998; Melone et al., 2001; Schmitt et al., 2003) . Fig. 3 . Glu uptake in oocytes injected with mRNA from the PFC of a schizophrenic patient.
3 H-Glu uptake in oocytes injected with mRNA from the PFC of a medication-free schizophrenic is greater than in those injected with mRNA from the PFC of 3 controls. Values are means Ϯ SEM (n ϭ 3-5), ***P Ͻ 0.001 (Fisher's PDLS test following one-way ANOVA).
